The scientist’s investigation covers issues in Breast cancer, Internal medicine, Oncology, Cancer and Neoadjuvant therapy. His research integrates issues of Clinical trial, Disease and Chemotherapy regimen in his study of Breast cancer. His Oncology research incorporates elements of Chemotherapy, Docetaxel, Tumor-infiltrating lymphocytes, Pathology and Hazard ratio.
His Cancer study incorporates themes from Histone deacetylase, Cancer research and Bioinformatics. Carsten Denkert has included themes like Immunohistochemistry, Immunology, Endocrinology, Carcinoma and Ovarian cancer in his Cancer research study. The study incorporates disciplines such as Anthracycline, Ductal carcinoma, Lapatinib, Bevacizumab and Prospective cohort study in addition to Neoadjuvant therapy.
Carsten Denkert mainly investigates Internal medicine, Oncology, Breast cancer, Cancer and Cancer research. His study on Internal medicine is mostly dedicated to connecting different topics, such as Endocrinology. The concepts of his Oncology study are interwoven with issues in Taxane, Biomarker, Tumor-infiltrating lymphocytes and Anthracycline.
His Breast cancer research integrates issues from Hazard ratio and Clinical trial, Pathology. His Cancer study frequently draws connections between adjacent fields such as Immune system. His work in Cancer research addresses subjects such as Ovarian cancer, which are connected to disciplines such as Serous fluid.
Carsten Denkert mainly focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer. Internal medicine is closely attributed to Placebo in his work. His work on Adjuvant as part of general Oncology research is frequently linked to In patient, bridging the gap between disciplines.
His Breast cancer study combines topics from a wide range of disciplines, such as Cancer research, Tumor-infiltrating lymphocytes and Multivariate analysis. His Chemotherapy research includes themes of Stage, Metastatic breast cancer, Palbociclib and Anthracycline. In Cancer, Carsten Denkert works on issues like Omics, which are connected to Metabolomics, Proteomics and Transcriptome.
His main research concerns Internal medicine, Breast cancer, Oncology, Chemotherapy and Neoadjuvant therapy. Cancer covers he research in Breast cancer. The Cancer study combines topics in areas such as Text mining, Proteomics, Omics and Metabolomics.
His biological study spans a wide range of topics, including Carboplatin, Triple-negative breast cancer, Trastuzumab and Clinical trial. He interconnects Triple Negative Breast Neoplasms, Neuroblastoma RAS viral oncogene homolog, PTEN and HRAS in the investigation of issues within Chemotherapy. His study in Neoadjuvant therapy is interdisciplinary in nature, drawing from both Multivariate analysis, Placebo, Pathological and Pooled analysis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Balazs Györffy;Andras Lanczky;Aron C. Eklund;Carsten Denkert.
Breast Cancer Research and Treatment (2010)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa.
Journal of Clinical Oncology (2012)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado;C. Denkert;S. Demaria;N. Sirtaine.
Annals of Oncology (2015)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert;Sibylle Loibl;Aurelia Noske;Marc Roller.
Journal of Clinical Oncology (2010)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine.
Annals of Oncology (2014)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn.
Journal of Clinical Oncology (2015)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer.
Lancet Oncology (2018)
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies;Frederick Klauschen;Bruno V. Sinn;Balázs Győrffy.
PLOS ONE (2012)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2017)
Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur.
The New England Journal of Medicine (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: